Insulet Corporation

Insulet Corporation is a US-based medical device company headquartered in Acton, Massachusetts. Founded in 2000 with revenue of $2.71 billion in 2025, the company employs approximately 3,000 people and operates manufacturing facilities in the United States and Costa Rica.

Business Overview

Insulet is the pioneer and market leader in tubeless insulin pump technology with its Omnipod product line. The company has achieved exceptional growth of 30.73% year-over-year, driven by strong adoption of the Omnipod 5 automated insulin delivery system. Insulet's subscription model provides recurring revenue from consumable pod sales.

Key Strengths

• First-to-market tubeless insulin pump with category-defining technology
• Exceptional 30.73% annual revenue growth trajectory
• $600M+ investment in proprietary manufacturing capabilities
• #1 prescribed insulin pump brand in US market
• Recurring revenue model with high-margin consumable pods

Challenges & Outlook

Insulet's single-product focus creates vulnerability to competitive threats, particularly from Medtronic's next-generation patch pump and larger pharmaceutical entrants. Geographic concentration in North America limits growth diversification. The company must continue investing heavily in manufacturing capacity to meet surging global demand while maintaining quality standards for Class III medical devices.